Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Total Current Liabilities (2016 - 2025)

InspireMD filings provide 16 years of Total Current Liabilities readings, the most recent being $10.7 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 39.52% to $10.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 39.52% increase, with the full-year FY2025 number at $10.7 million, up 39.52% from a year prior.
  • Total Current Liabilities hit $10.7 million in Q4 2025 for InspireMD, down from $10.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $10.8 million in Q3 2025 to a low of $2.9 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $4.9 million (2023), compared with a mean of $5.8 million.
  • Biggest five-year swings in Total Current Liabilities: increased 2.48% in 2023 and later surged 54.9% in 2024.
  • InspireMD's Total Current Liabilities stood at $4.3 million in 2021, then grew by 16.63% to $5.1 million in 2022, then rose by 18.74% to $6.0 million in 2023, then grew by 27.54% to $7.7 million in 2024, then soared by 39.52% to $10.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $10.7 million (Q4 2025), $10.8 million (Q3 2025), and $9.1 million (Q2 2025) per Business Quant data.